170 related articles for article (PubMed ID: 8706812)
1. Amphotericin B Lipid Complex (Abelcet) in the treatment of invasive mycoses: the North American experience.
Lister J
Eur J Haematol Suppl; 1996; 57():18-23. PubMed ID: 8706812
[TBL] [Abstract][Full Text] [Related]
2. Efficacy of amphotericin B lipid complex injection (ABLC) in bone marrow transplant recipients with life-threatening systemic mycoses.
Wingard JR
Bone Marrow Transplant; 1997 Feb; 19(4):343-7. PubMed ID: 9051244
[TBL] [Abstract][Full Text] [Related]
3. Amphotericin B lipid complex in pediatric patients with invasive fungal infections.
Walsh TJ; Seibel NL; Arndt C; Harris RE; Dinubile MJ; Reboli A; Hiemenz J; Chanock SJ
Pediatr Infect Dis J; 1999 Aug; 18(8):702-8. PubMed ID: 10462340
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and safety of amphotericin B lipid complex in 548 children and adolescents with invasive fungal infections.
Wiley JM; Seibel NL; Walsh TJ
Pediatr Infect Dis J; 2005 Feb; 24(2):167-74. PubMed ID: 15702047
[TBL] [Abstract][Full Text] [Related]
5. Amphotericin B lipid complex for invasive fungal infections: analysis of safety and efficacy in 556 cases.
Walsh TJ; Hiemenz JW; Seibel NL; Perfect JR; Horwith G; Lee L; Silber JL; DiNubile MJ; Reboli A; Bow E; Lister J; Anaissie EJ
Clin Infect Dis; 1998 Jun; 26(6):1383-96. PubMed ID: 9636868
[TBL] [Abstract][Full Text] [Related]
6. ABELCET treatment.
Boyle JA; Swenson CE
J Clin Pharmacol; 1999 Apr; 39(4):427-8. PubMed ID: 10197303
[No Abstract] [Full Text] [Related]
7. A comparative analysis of lipid-complexed and liposomal amphotericin B preparations in haematological oncology.
Clark AD; McKendrick S; Tansey PJ; Franklin IM; Chopra R
Br J Haematol; 1998 Oct; 103(1):198-204. PubMed ID: 9792308
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and safety of amphotericin B lipid complex injection (ABLC) in solid-organ transplant recipients with invasive fungal infections.
Linden P; Williams P; Chan KM
Clin Transplant; 2000 Aug; 14(4 Pt 1):329-39. PubMed ID: 10945204
[TBL] [Abstract][Full Text] [Related]
9. The efficacy of two different lipid-based amphotericin B in neonatal Candida septicemia.
Cetin H; Yalaz M; Akisu M; Hilmioglu S; Metin D; Kultursay N
Pediatr Int; 2005 Dec; 47(6):676-80. PubMed ID: 16354223
[TBL] [Abstract][Full Text] [Related]
10. Assessing the antifungal activity, pharmacokinetics, and tissue distribution of amphotericin B following the administration of Abelcet and AmBisome in combination with caspofungin to rats infected with Aspergillus fumigatus.
Wasan KM; Sivak O; Rosland M; Risovic V; Bartlett K
J Pharm Sci; 2007 Jul; 96(7):1737-47. PubMed ID: 17080414
[TBL] [Abstract][Full Text] [Related]
11. Assessment of nephrotoxicity in patients receiving amphotericin B lipid complex: a pharmacosurveillance study in Spain.
Aguado JM; Lumbreras C; González-Vidal D;
Clin Microbiol Infect; 2004 Sep; 10(9):785-90. PubMed ID: 15355408
[TBL] [Abstract][Full Text] [Related]
12. Efficacy of Abelcet alone, or in combination therapy, against experimental central nervous system aspergillosis.
Clemons KV; Parmar R; Martinez M; Stevens DA
J Antimicrob Chemother; 2006 Aug; 58(2):466-9. PubMed ID: 16760192
[TBL] [Abstract][Full Text] [Related]
13. Amphotericin B lipid complex.
Rapp RP; Gubbins PO; Evans ME
Ann Pharmacother; 1997 Oct; 31(10):1174-86. PubMed ID: 9337444
[TBL] [Abstract][Full Text] [Related]
14. Overview of the lipid formulations of amphotericin B.
Dupont B
J Antimicrob Chemother; 2002 Feb; 49 Suppl 1():31-6. PubMed ID: 11801578
[TBL] [Abstract][Full Text] [Related]
15. Efficacy of Abelcet and caspofungin, alone or in combination, against CNS aspergillosis in a murine model.
Imai J; Singh G; Fernandez B; Clemons KV; Stevens DA
J Antimicrob Chemother; 2005 Jul; 56(1):166-71. PubMed ID: 15917284
[TBL] [Abstract][Full Text] [Related]
16. Emerging fungal pathogens, drug resistance and the role of lipid formulations of amphotericin B in the treatment of fungal infections in cancer patients: a review.
Viscoli C; Castagnola E
Int J Infect Dis; 1998-1999 Winter; 3(2):109-18. PubMed ID: 10225990
[TBL] [Abstract][Full Text] [Related]
17. Amphotericin B lipid complex at 3 mg/kg/day for treatment of invasive fungal infections in adults with haematological malignancies.
Martino R; Subirá M; Sureda A; Sierra J
J Antimicrob Chemother; 1999 Oct; 44(4):569-72. PubMed ID: 10588324
[TBL] [Abstract][Full Text] [Related]
18. [Role of Abelcet in children with febrile neutropenia].
Le Guyader N; Auvrignon A; Demontoux V; Fasola S; Fratta A; Pellegrino B; Benoit G; Leverger G
Pathol Biol (Paris); 2004 Nov; 52(9):550-5. PubMed ID: 15531121
[TBL] [Abstract][Full Text] [Related]
19. [Amphotericin B and its lipid formulations].
Ritter J
Mycoses; 2002; 45 Suppl 3():34-8. PubMed ID: 12690969
[TBL] [Abstract][Full Text] [Related]
20. Efficacy of amphotericin B lipid complex in the treatment of invasive fungal infections in immunosuppressed paediatric patients.
Herbrecht R; Auvrignon A; Andrès E; Guillemain R; Suc A; Eyer D; Pailler C; Letscher-Bru V; Leverger G; Schaison G
Eur J Clin Microbiol Infect Dis; 2001 Feb; 20(2):77-82. PubMed ID: 11305476
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
